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I
t is well recognized that there is a signiﬁcant delay
from the time clinical research ﬁndings are ﬁrst
reported and when the results become an integral
part of clinical care. With the understanding that the
prevalence and incidence of diabetes is increasing world-
wide, and that the resulting complications are a major
contributor to morbidity and mortality, the need for more
rapid clinical translation of research ﬁndings for diabetes
could not be greater.
Speciﬁcally, a large amount of clinical research data has
been reported in the recent past that is of great interest to
the provider caring for individuals with diabetes. Much of
the emphasis for research has been devoted to under-
standing the contribution of hyperglycemia and its treat-
ment on macrovascular disease. For example, within the
last decade, we have not only recognized the pivotal role
that chronic hyperglycemia, as assessed with A1C levels,
contributes to the development of microvascular compli-
cations, but we have recognized the importance of glyce-
mia in contributing to cardiovascular disease (CVD) (1,2).
Observations from large-scale prospective trials over the
last couple of years have reported that in high-risk sub-
jects, intensive therapy to lower A1C levels below sug-
gested targets may not be beneﬁcial or may increase
mortality (3–5). However, as observed from these studies,
we also learned that certain subsets of patients with type
2 diabetes may actually beneﬁt from intensive glycemic
control (3). The most recent analysis, reported in May
2010, has now suggested that mortality may actually be
greater for those who maintain a higher A1C level despite
attempts at intensive glycemic management (6). Interest-
ingly, the excess mortality in the group randomized to
intensive glycemic management was only seen at A1C
levels greater than 7% (6). Thus, the ﬁndings regarding A1C
targets for selected patient populations with type 2 diabe-
tes continue to evolve to this day and remain important
data for clinicians.
In addition to understanding the role of speciﬁc treat-
ment of hyperglycemia, an equally important observation
has been occurring with the recognition that nondiabetic
hyperglycemia is associated with cardiovascular disease.
Yet, this area of research does not appear to have been
given as much attention as the high-proﬁle prospective
studies addressing intensive management of hyperglyce-
mia for cardiovascular disease in individuals already diag-
nosed with type 2 diabetes. In this regard, it has been
known for years that glycemia considered to be in the
“nondiabetic” range, i.e., 2-h postprandial glucose levels
deﬁned as impaired glucose tolerance, has signiﬁcant
clinical implications related to increased CVD mortality
(7–12). Of great interest, a very recent and additional
analysis of the Diabetes Epidemiology: Collaborative Anal-
ysis of Diagnostic Criteria in Europe (DECODE) study
reported incredibly provocative data. Speciﬁcally, the in-
vestigators restricted the comparison to individuals with
normoglycemia, i.e., mean 2-h glucose levels in one group
of men and women of approximately 78 and 81 mg/dl,
respectively, compared with a second group of men and
women with 2-h values of approximately 112 and 113
mg/dl, respectively (13). Yet, even in this range of glyce-
mia, elevated 2-h postprandial glucose conveyed increased
mortality risk from CVD but not from non-CVD and
suggests concern with nondiabetic hyperglycemia at post-
prandial levels considered in the normal range. With these
observations, a relevant question would be: Why is 2-h
glucose not routinely monitored by clinicians in an effort
to stratify CVD risk? Clearly, this is a complicated question
for which opinions vary widely and one for which there is
no single right or wrong answer. But, as elegantly re-
viewed, it is known that the performance and interpreta-
tion of the oral glucose tolerance test has been shown to
be inconsistent (14).
Given these concerns with oral glucose tolerance test-
ing, and with the recent recommendation that the A1C test
(as an objective test for chronic glycemia) can serve to
diagnose diabetes, the next logical question is whether
A1C can serve to stratify CVD risk in individuals with
“nondiabetic” hyperglycemia. This is an important ques-
tion and could potentially signal a paradigm shift in how
we screen for the increasing number of individuals felt to
be at great risk for CVD. Furthermore, having a reliable
and stable clinical marker for disease risk would allow for
more aggressive clinical interventions to prevent progres-
sion of the underlying pathologies relevant to glycemia.
With the publication of the EPIC-Norfolk data, we had one
of the ﬁrst reports associating A1C levels considered to be
in the normal range with disease outcomes. A1C level was
continuously related to subsequent all-cause, cardiovascu-
lar, and ischemic heart disease mortality through the
whole population distribution, with lowest rates in those
with A1C concentrations below 5% (15). These observa-
tions from over 9 years ago are considerably expanded by
From the Joint Program on Diabetes, Endocrinology and Metabolism of the
Pennington Biomedical Research Center, LSU System, Baton Rouge, Loui-
siana, and the Louisiana State University Health Science Center School of
Medicine, New Orleans, Louisiana.
Corresponding author: William T. Cefalu, william.cefalu@pbrc.edu.
DOI: 10.2337/db10-0800
© 2010 by the American Diabetes Association. Readers may use this article as
long as the work is properly cited, the use is educational and not for proﬁt,
and the work is not altered. See http://creativecommons.org/licenses/by
-nc-nd/3.0/ for details.
See accompanying article, p. 2020.
COMMENTARY
1868 DIABETES, VOL. 59, AUGUST 2010 diabetes.diabetesjournals.orga report in this issue of Diabetes. Speciﬁcally, Matsushita
et al. (16) report on the continuous association of A1C in
the nondiabetic range and progression of heart failure. The
authors evaluated A1C levels in a very large cohort of over
11,000 individuals as part of the Atherosclerosis Risk in
Communities Study. After adjustment for covariates, the
hazard ratio of incident heart failure was increased in the
cohort with A1C levels of 5.5–6.0% and even further in the
cohort represented by A1C levels of 6.0–6.4%. Additional
studies reported recently for this cohort demonstrated
that the A1C level obtained at baseline was associated
with adverse cardiovascular outcomes (17). For A1C val-
ues of 5.0%, 5.0 to 5.5%, 5.5 to 6.0%, 6.0 to 6.5%, and
6.5% or greater, the multivariable-adjusted hazard ratios
for coronary heart disease were 0.96, 1.00 (reference),
1.23, 1.78, and 1.95, respectively. As an A1C level of 6.5%
has been suggested for diagnosis for type 2 diabetes, the
increased risk noted in individuals observed to have an
A1C value of 6.5% clearly emphasizes the increased risk
attributed to glycemia considered in the “nondiabetic”
range. Thus, the recent observations strongly support the
association of nondiabetic hyperglycemia to an increased
risk for CVD.
With the above data outlining the clinical signiﬁcance of
“nondiabetic” hyperglycemia and that the A1C level ap-
pears to be a reasonable marker at this stage, is it time to
make ﬁrm recommendations for clinicians to initiate in-
terventions for A1C in this range? If that happens, it would
clearly represent a huge leap in clinical translation of
research data. The problem, as clearly understood, is that
we have no evidence suggesting that treatment of nondi-
abetic glycemia based on a single A1C level 6.5% will
ultimately have beneﬁts on CVD. To gather such evidence,
prospective studies will need to be done that will take
years to complete, will involve a large number of subjects,
and will take signiﬁcant resources. However, for now, we
can’t ignore the recent data that an A1C level in the
high-normal nondiabetic range may indeed serve as a
simple clinical marker that heightens our awareness of
individuals at increased CVD risk.
With knowledge of this information, shouldn’t providers
now be encouraged to provide a comprehensive evalua-
tion for other comorbidities, i.e., hypertension, obesity,
and dyslipidemia, that are present in individuals at levels
of A1C suggestive of increased risk? Would it not make
sense to strongly encourage providers to aggressively treat
these risk factors based on intervention trials that have
demonstrated effectiveness? At this stage, shouldn’t the
A1C in the high-normal nondiabetic range also signal the
need for comprehensive education of the patient regarding
CVD risk and allow for initiation of effective lifestyle
modiﬁcation? Such a strategy appears to be an extremely
reasonable and rational approach, and, based on known
evidence, such clinical translation of current A1C data in
the “nondiabetic” range to clinical practice will be truly
representative of the “art of medicine.”
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